Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859129 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
A Phase 1 study of Hypertriglyceridemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT02859129 is a Phase 1 study of Hypertriglyceridemia that has completed, run by AstraZeneca. The registered enrollment target is 114 participants, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02859129, a Phase 1 study of Hypertriglyceridemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
Conditions Studied
Interventions
- DRUG rosuvastatin 40 mg tablet
- DRUG Epanova™ QD (2 x 1 g capsules)
- DRUG Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose
- DRUG Multiple (20) oral doses of 2 g Vascepa® every 12 hours
Study Locations (1)
New Jersey
- Celerion - Neptune City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2013-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02859129
The ClinicalTrials.gov registry entry for NCT02859129 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 172-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (34% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 4 interventions - of which rosuvastatin 40 mg tablet is the first listed.
NCT02859129 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02859129 about?
NCT02859129 is a clinical study titled "Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)". This study is intended to evaluate the potential 2-way reciprocal interaction between multiple doses of Epanova™ and a single dose of rosuvastatin
What is the current status of trial NCT02859129?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2013-09. Estimated completion is 2013-11.
What conditions does trial NCT02859129 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT02859129?
The interventions under investigation include: rosuvastatin 40 mg tablet (DRUG), Epanova™ QD (2 x 1 g capsules) (DRUG), Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose (DRUG), Multiple (20) oral doses of 2 g Vascepa® every 12 hours (DRUG).
Who is sponsoring clinical trial NCT02859129?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02859129 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
ACTIVE NOT RECRUITING · Phase 1
-
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
COMPLETED · Phase 1
-
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
COMPLETED · Phase 1
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.